N-803 (IL-15 Superagonist)

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), ImmunityBio, Inc.

Conditions

HIV InfectionHigh-risk Prostate CancerLong COVID

Phase 1

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Active, not recruitingNCT04340596

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection

Start: 2021-05-21End: 2026-12-30Updated: 2025-03-25

Phase 2

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Not yet recruitingNCT06765954

ImmunityBio, Inc.High-risk Prostate Cancer

Start: 2025-06-01End: 2031-06-30Target: 20Updated: 2025-05-06

A Study to Assess Anktiva in Patients With Long Covid-19.

RecruitingNCT07108036

ImmunityBio, Inc.Long COVID

Start: 2025-11-14End: 2026-10-01Target: 20Updated: 2026-03-27